Basilea Pharmaceutica Ltd

Activities: Research & Development

Trending Articles

  1. Driving sustainable transition in pharmaceutical packaging The pharmaceutical industry, although dedicated to improving human health, is increasingly grappling with the challenge of balancing this mission with environmental...
  2. Blood plasma processing: when every drop counts Plasma derivatives obtained from human blood support the treatment of various diseases — from haemophilia and antigen defects to COVID-19. The products are in high demand and...
  3. Olon continues its growth with a new acquisition The acquisition of Huvepharma Italia Srl increases production capacity and expands market presence
  4. AI in IT/OT integration: how technology can overcome cybersecurity hurdles Manufacturing Chemist (MC) spoke to Rene Hackl (RH), Managing Director at Phytools about how artificial intelligence (AI) can revolutionise IT/OT integration
  5. Have you seen the latest from METTLER TOLEDO on advanced filling solutions? Join METTLER TOLEDO’s free webinar to explore weight-based filling for greater accuracy and control

Upcoming event

Pharmaconex

8-10 September 2024 | Conference | Cairo, Egypt See all

Related Content

Research & Development

Spexis sells preclinical antibiotics programme to Basilea

The CHF 2m deal gives Basilea ownership of a novel programme of Gram-negative bacteria-targeting antibiotics
Finance

Spexis announces sale of preclinical antibiotics programme to Basilea

Basilea to pay up to CHF2m for a preclinical programme with novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains
Research & Development

Forge and Basilea partner on antibiotic discovery

Forge Therapeutics’s platform will be used by Basilea Pharmaceutica to develop inhibitors against two historically difficult-to-drug, unexploited antibiotic targets
Research & Development

Basilea awarded up to US$100m contract from BARDA

To advance clinical Phase III programme for ceftobiprole antibiotic
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Latest EU drug approvals span range of health issues

Cancer was again at the forefront of the NMEs reaching the market in 2015, but new drugs also benefited other disease areas. Dr Sarah Houlton looks at the latest therapeutic arrivals
Research & Development

Basilea's Chief Technology Officer to retire

Dr Günter Ditzinger named as successor Dr Ingrid Heinze-Krauss
Research & Development

Consortium signs deal with Basilea to develop targeted cancer therapy

Clinical Phase I testing of panRAF kinase inhibitors is expected to start this year
Subscribe now